Decoding Karuna Therapeutics Inc (KRTX): A Strategic SWOT Insight [Yahoo! Finance]
Karuna Therapeutics, Inc. (KRTX)
Company Research
Source: Yahoo! Finance
Weaknesses: Clinical-stage status with significant ongoing R&D expenses and no product revenue. Opportunities: Potential market expansion through strategic collaborations and additional indications for KarXT. Threats: Intense competition in the neuropsychiatric drug market and regulatory hurdles. Warning! GuruFocus has detected 5 Warning Signs with KRTX. On February 22, 2024, Karuna Therapeutics Inc ( NASDAQ:KRTX ), a clinical-stage biopharmaceutical company, filed its annual report ( 10-K ) with the SEC, offering a comprehensive view of its financial health and strategic positioning. With a focus on developing novel therapies for neuropsychiatric conditions, KRTX's lead product candidate, KarXT, is an oral modulator of muscarinic receptors with potential applications in schizophrenia and Alzheimer's disease psychosis. As of the end of the fiscal year 2023, the company reported a substantial market valuation of $5,872.6 million, with 38.15 million shares of common stock outst
Show less
Read more
Impact Snapshot
Event Time:
KRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRTX alerts
High impacting Karuna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KRTX
News
- PureTech Proposes $100 Million Capital Return [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion [Yahoo! Finance]Yahoo! Finance
- Loss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-Term [Yahoo! Finance]Yahoo! Finance
- Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor [Yahoo! Finance]Yahoo! Finance
- Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short Position [Yahoo! Finance]Yahoo! Finance
KRTX
Earnings
- 2/22/24 - Miss
KRTX
Sec Filings
- 3/18/24 - Form 4
- 3/18/24 - Form 4
- 3/18/24 - Form 4
- KRTX's page on the SEC website